文献速递心血管CT

非阻塞性冠状动脉斑块的进展:来自PARADIGM注册研究的实用CCTA风险评分

Progression of non-obstructive coronary plaque: a practical CCTA-based risk score from the PARADIGM registry.
PubMed 文献 · Eur Radiol · 2023-09-26

基于PARADIGM注册研究,纳入370例推导队列和219例验证队列,均有两次临床指征CCTA、基线非阻塞性CAD且无高危斑块。推导队列28%出现疾病进展,模型含点状钙化斑块数、低衰减成分斑块数、25-49%狭窄、分叉斑块数及两次CCTA间隔,C统计量推导0.732、验证0.668。

要点

  • 基线CCTA无高危斑块的非阻塞性CAD患者中,约28%在约3.3年内进展为≥50%狭窄和/或高危斑块。
  • 点状钙化斑块数(OR 4.59)和低衰减成分斑块数(OR 3.73)是进展的强预测因子。
  • 该CCTA风险评分在推导队列C统计量0.732,验证队列0.668。

核心结论

  • 基于CCTA的新风险评分是简单实用的工具,可预测已知非阻塞性CAD患者的中期疾病进展。

研究设计与样本

  • PARADIGM注册研究,推导队列370例、验证队列219例,均有两次临床指征CCTA、基线非阻塞性CAD且无高危斑块(≥2个高危特征)。

关键影像表现/征象

  • 疾病进展定义为随访CCTA新出现≥50%狭窄和/或高危斑块,推导队列104例(28%)发生进展。
  • 两次CCTA中位时间间隔3.3年(2.7-4.8)。
  • 多变量logistic回归显示点状钙化斑块数OR 4.59(95%CI 1.69-12.48)。
  • 低衰减成分斑块数OR 3.73(95%CI 1.46-9.52),25-49%狭窄严重度OR 2.71(95%CI 1.62-4.50)。
  • 分叉斑块数OR 1.47(95%CI 1.17-1.84),两次CCTA间隔OR 1.21(95%CI 1.02-1.42)。

诊断标准与关键数值

  • 模型C统计量推导队列0.732(95%CI 0.676-0.788),验证队列0.668(95%CI 0.583-0.752)。
  • 基线高危斑块定义为≥2个高危特征,此类患者被排除。
  • 疾病进展定义为随访CCTA新出现≥50%狭窄和/或高危斑块。

临床应用与阅片要点

  • 该CCTA风险评分有助于指导非阻塞性CAD患者的影像随访时机和治疗策略。
  • 不同科学学会对非阻塞性CAD患者重复CCTA的临床使用尚无明确推荐。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: No clear recommendations are endorsed by the different scientific societies on the clinical use of repeat coronary computed tomography angiography (CCTA) in patients with non-obstructive coronary artery disease (CAD). This study aimed to develop and validate a practical CCTA risk score to predict medium-term disease progression in patients at a low-to-intermediate probability of CAD.

METHODS: Patients were part of the Progression of AtheRosclerotic PlAque Determined by Computed Tomographic Angiography Imaging (PARADIGM) registry. Specifically, 370 (derivation cohort) and 219 (validation cohort) patients with two repeat, clinically indicated CCTA scans, non-obstructive CAD, and absence of high-risk plaque (≥ 2 high-risk features) at baseline CCTA were included. Disease progression was defined as the new occurrence of ≥ 50% stenosis and/or high-risk plaque at follow-up CCTA.

RESULTS: In the derivation cohort, 104 (28%) patients experienced disease progression. The median time interval between the two CCTAs was 3.3 years (2.7-4.8). Odds ratios for disease progression derived from multivariable logistic regression were as follows: 4.59 (95% confidence interval: 1.69-12.48) for the number of plaques with spotty calcification, 3.73 (1.46-9.52) for the number of plaques with low attenuation component, 2.71 (1.62-4.50) for 25-49% stenosis severity, 1.47 (1.17-1.84) for the number of bifurcation plaques, and 1.21 (1.02-1.42) for the time between the two CCTAs. The C-statistics of the model were 0.732 (0.676-0.788) and 0.668 (0.583-0.752) in the derivation and validation cohorts, respectively.

CONCLUSIONS: The new CCTA-based risk score is a simple and practical tool that can predict mid-term CAD progression in patients with known non-obstructive CAD.

CLINICAL RELEVANCE STATEMENT: The clinical implementation of this new CCTA-based risk score can help promote the management of patients with non-obstructive coronary disease in terms of timing of imaging follow-up and therapeutic strategies.

KEY POINTS: • No recommendations are available on the use of repeat CCTA in patients with non-obstructive CAD. • This new CCTA score predicts mid-term CAD progression in patients with non-obstructive stenosis at baseline. • This new CCTA score can help guide the clinical management of patients with non-obstructive CAD.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Pontone G, Rossi A, Baggiano A, et al. Progression of non-obstructive coronary plaque: a practical CCTA-based risk score from the PARADIGM registry. Eur Radiol. 2023. PMID: 37750979. doi:10.1007/s00330-023-09880-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。